200 related articles for article (PubMed ID: 32966971)
1. Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.
Wang X; Zhang H; Zhang Q; Guan M; Sheng S; Mo W; Zou M; Li J; Bi J; Tang X; Zeng H; He J; Xu G; Li P; Xue Y
Am J Nephrol; 2020; 51(10):806-814. PubMed ID: 32966971
[TBL] [Abstract][Full Text] [Related]
2. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
4. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW
Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624
[TBL] [Abstract][Full Text] [Related]
5. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
Zhang J; Xian TZ; Wu MX; Li C; Pan Q; Guo LX
Cardiovasc Diabetol; 2020 Apr; 19(1):48. PubMed ID: 32334592
[TBL] [Abstract][Full Text] [Related]
7. The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
Retnakaran R; Pu J; Ye C; Emery A; Kramer CK; Zinman B
Cardiovasc Diabetol; 2023 Mar; 22(1):50. PubMed ID: 36894921
[TBL] [Abstract][Full Text] [Related]
8. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes.
Fayfman M; Galindo RJ; Rubin DJ; Mize DL; Anzola I; Urrutia MA; Ramos C; Pasquel FJ; Haw JS; Vellanki P; Wang H; Albury BS; Weaver R; Cardona S; Umpierrez GE
Diabetes Care; 2019 Mar; 42(3):450-456. PubMed ID: 30679302
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
[TBL] [Abstract][Full Text] [Related]
10. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
[TBL] [Abstract][Full Text] [Related]
12. Intervention using vitamin D for elevated urinary albumin in type 2 diabetes mellitus (IDEAL-2 Study): study protocol for a randomised controlled trial.
Taheri S; Asim M; Al Malki H; Fituri O; Suthanthiran M; August P;
Trials; 2018 Apr; 19(1):230. PubMed ID: 29665833
[TBL] [Abstract][Full Text] [Related]
13. The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial.
Retnakaran R; Ye C; Emery A; Kramer CK; Zinman B
Nat Commun; 2022 Oct; 13(1):6109. PubMed ID: 36244997
[TBL] [Abstract][Full Text] [Related]
14. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
16. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
17. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
Yan M; Wen Y; Yang L; Wu X; Lu X; Zhang B; Huang W; Li P
Trials; 2016 May; 17(1):259. PubMed ID: 27216240
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.
Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M
Diabetes Obes Metab; 2017 Nov; 19(11):1610-1619. PubMed ID: 28636754
[TBL] [Abstract][Full Text] [Related]
20. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
